Integrating Cardiovascular Endpoints into toxicology studies: Preliminary Results from An Industry Survey Simon Authier, DVM, MBA, PhD Director - Safety.

Slides:

Advertisements

Similar presentations

Group 1B: Suitable Top Concentration for Tests with Mammalian Cells -MLA Workgroup- 5 TH INTERNATIONAL WORKSHOP ON GENOTOXICITY TESTING Basle, August 17-19,

Advertisements

Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)

Welcome slide. A more risk-based approach to quality assurance in higher education in England June 2012 consultation events Heather Fry Director (Education.

South Northamptonshire Council Stock Transfer Ballot Project Choice of Landlord Model Panel Friday 17 th February 2006.

Disposal of Unused or Expired Drugs Attorneys General Education Program Public Policy Conference THE PHARMACEUTICAL INDUSTRY: ECONOMICS, REGULATION, AND.

Tufts University Teaching Conference Development of Clinical Reasoning Nicholas Frank, DVM, PhD, DACVIM Claire Sharp, BVMS, MS, DACVECC Cummings School.

Data for Smarter Decisions: How to Access Fast, Free Findings from GMAC ® Researchers.

Mitochondrial Manipulation Technologies: Preclinical Considerations

Phone: (919) Fax: (919) CFR Part 11 FDA Public Meeting Comments Presented by: M. Rita.

1 FDA DRAFT GUIDANCE ON CLINICAL TRIAL DATA MONTORING COMMITTEES Susan S. Ellenberg, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics.

Desired Skills and Traits for Future Faculty J.R. Haywood Department Pharmacology & Toxicology Michigan State University Pharmacology Graduate Directors.

Climate Change Adaptation Planning Discussion Questions NMFWA 2014.

Copyright © 2014 by The University of Kansas Member Survey of Process: Ratings of Satisfaction.

CHESSS CEN Horizontal European Service Standardization Strategy Module 3: “Safety in the Delivery of Services” prepared by Axel Mangelsdorf Berlin University.

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

DIES ASEAN- QA Training Workshop on External Quality Assurance Manila 16 th – 19 th of October 2012 Roles and Responsibilities of the Assessors (Do’s and.

Development and application of guidance documents – industry view Dr Martin Schaefer ECCA-ECPA Conference March 2014.

Decision Making Mrs. Nations Introduction to Business and Technology.

Adding Safety Pharm Endopoints To General Tox Studies - II Michael J Engwall, DVM, PhD Principal Scientist Safety and Exploratory Pharmacology Toxicology.

Integrating functional CNS observations into toxicology studies: Preliminary Results from An Industry Survey Simon Authier, DVM, MBA, PhD Director - Safety.

Respiratory Safety Pharmacology Endpoints in Toxicology Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North.

Research Auditing Presented by: Darlene Krueger, MBA RN CCRA Chief, GCP Auditing & Training VA Cooperative Studies Program Albuquerque, NM.

Good Catch Awards These awards are for the purpose of encouraging contributions to the Patient Safety net regarding averted medication errors. When you.

Presented by: Louise Desjardins, M.Sc., Ph.D. Executive Director December 3, 2014.

Teaching and Learning Conversations your name Your job Your Institution Your contact details ( /twitter/website) a photograph of you title of your.

Beyond and Decisions: From Problem Formulation to Dose- Response.

Comprehensive Unit Based Safety Program    A webinar series for QI Managers, Nurse Leaders and others supporting healthcare improvement in Wisconsin’s.

1 Leveraging the WTO/TBT Agreement New Delhi, India September 11, 2008 Elise Owen Representative for China and India Affairs American National Standards.

FDA – TPSAC – June 8-9, 2010 Preliminary Information Concerning the Establishment of a List of Harmful and Potentially Harmful Tobacco Product Constituents:

Advanced Higher Modern Studies Research Methods Research Methods.

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

Safety Pharmacology Society Webinar Series: Safety Pharmacology Endpoints: Integration into Toxicology Studies Integrating functional CNS observations.

Investment Attractiveness Index with the support of the InMind research company EBA Investment Attractiveness INDEX I/2011 Conducted by EBA with the support.

Research Animal Welfare & Scientific Integrity: An AAALAC International Perspective John F. Bradfield, DVM, PhD, DACLAM Senior Director, AAALAC International.

Consider Incorporating Respiratory Safety Pharmacology Measurements into Your Next Repeat Dose Toxicology Study September 14, 2012 Jeff Tepper, PhD, DABT.

EFSPI Statistical Leaders Meeting 8 th June

Part Two Corruption Assessments Photos by Adam Rogers/UNCDF.

API 17N (and Q) Subsea Production System Reliability, Integrity, and Technical Risk Management.

Company: Cincinnati Insurance Company Position: IT Governance Risk & Compliance Service Manager Location: Fairfield, OH About the Company : The Cincinnati.

C HU H AI C OLLEGE O F H IGHER E DUCATION D EPARTMENT O F C OMPUTER S CIENCE Preparation of Final Year Project Report Bachelor of Science in Computer Science.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Pilot Grant Program EGAD Study OCCUPATIONAL & ENVIRONMENTAL HEALTH.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

12/4/031 Drug Safety and Risk Management Advisory Committee Advancing the Science of Proprietary Drug Name Review Paul J. Seligman, MD.

FDA’s Patient Advocacy Programs: Patient Representative Program & Patient Network Andrea Furia-Helms, MPH James Valentine, MHS Office of Special Health.

Scale and Scope of Highway Safety Manual Implementation in the Project Development Process For the Federal Highway Administration (FHWA) By Science Applications.

CONTINUING EVALUATION OF HIGHER EDUCATION PROGRAMS: CONCEPTUAL AND METHODOLOGICAL PERSPECTIVES AND CASE STUDY ANA MARIA CARNEIRO (NEPP – UNICAMP) CIBELE.

The Benefits of VICH to VICH Member Countries and Regions DONALD A. PRATER, DVM Director, U.S. FDA Europe Office Office of International Programs Office.

Quality Metrics of Performance of Research Ethics Committees Cristina E. Torres, PhD FERCAP Coordinator.

Evolving Best Practice in Governance Policy Developing Consumer Confidence in Risk Analysis Applied to Emerging Technologies Department of food science.

Australian Energy Regulator Public Forum Qld electricity distribution revenue proposals December 2014.

1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.

Dr. Lon Ferguson, CSP,CFPS Indiana University of Pennsylvania

Pre-Investigational New Drug (pre-IND) Meeting with FDA

Research Translation: Lessons from Dissemination and Implementation Research for Interventions Promoting Walking and Walkability August 18, am Pacific,

Formal Meetings between FDA and Sponsors of PDUFA Products

Regulatory Toxicology & Risk Assessment in Consulting

Regulatory Perspective

Private Sector Perspective: Key “Best Practices” that Strengthen Protection of Environment, Health and Safety while Facilitating Trade and Economic Development.

For more information, please see our methodology at:

Safety Committee Meeting November

Independent Expert Program Review (IEPR)

Beyond Science and Decisions: Problem Formulation to Dose Response

University Template Sample Slides June 2017.

HOW TO SET UP AND BEGIN BASIC SCIENCE RESEARCH

Expert Perspectives.

Self-Assessment Facilitators Guide Review and Resource Update

Presentation transcript:

Integrating Cardiovascular Endpoints into toxicology studies: Preliminary Results from An Industry Survey Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North America

Agenda Introduction Webinar survey Preliminary results from an Industry Survey Expert panel presentations – Pros: Marc Bailie (Michigan State University) – Cons: Mike Engwall (Amgen) – Regulatory perspective: John E Koerner (FDA) Open discussions Closing remarks

Introduction: Methodologies Technologies for Cardiovascular Investigations in Toxicology Studies Photo courtesy of DSIPhoto courtesy of EMKA

Webinar Poll Is the assessment of Cardiovascular endpoints in a toxicology study rather than a stand alone safety pharmacology study suitable to support IND studies in the majority of cases?

Preliminary Industry Survey Results Total of 361 participants

Preliminary Industry Survey Results Total of 361 participants

Preliminary Industry Survey Results

Slides of expert panel members

Questions for open discussions Based on your opinion, S7A safety pharmacology endpoints in regulatory toxicology studies are generally appropriate for: – CV safety pharmacology for small molecules ? – CV safety pharmacology for large molecules ? – As a standalone study?

Questions for open discussions In your organization, has the ability to add safety pharmacology endpoints onto regulatory toxicology studies had any of the following consequences? – Allowed you to manage safety risk more effectively? – Data contributed to the halting the progression of a compound? – Data addressed a specific concern and supported the continuation of a compound?

Questions for open discussions Based on your experience, please state any disadvantages of safety pharmacology investigations in toxicology studies? Based on your experience, please state any advantages of safety pharmacology investigations in toxicology studies?

Questions for open discussions Have you received regulatory feedback on inclusion of cardiovascular safety pharmacology in toxicology studies?

Thank you for your time and participation! Looking forward to see you in Phoenix for the 2012 Annual SPS meeting